| REVIEW ARTICLE |
|
| Year : 2018 | Volume
: 4
| Issue : 1 | Page : 15-20 |
|
|
Cardiology update 2018: The first quarter
Sunil Kumar Verma1, FA Farooqui1, Sridharan Umapathy1, H Gupta2
1 Department of Cardiology, CTC, AIIMS, Lucknow, Uttar Pradesh, India
2 Department of Medicine, KGMU, Lucknow, Uttar Pradesh, India
Correspondence Address:
Dr. Sunil Kumar Verma
Suite No. 24, 7th Floor, Department of Cardiology, CTC, AIIMS, Ansari Nagar, New Delhi - 110 029
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpcs.jpcs_14_18
|
|
|
Trials addressing the PCSK9 inhibitors, wearable cardioverter defibrillator, genotype-guided antiplatelet therapy, his bundle pacing, and therapies for HFpEF were discussed in American College of Cardiology 2018. TASMINH4 evaluated the need for self-monitoring and telemonitoring of blood pressure in the management of patients with poorly controlled blood pressure. In heart failure, issues regarding temporal trends and patterns of incidence, NT-proBNP, HeartMate pump, immunosuppression (sirolimus versus calcineurin) in heart transplant recipients, and aspirin use were evaluated in various trials. Drug-eluting balloon, MiStent, Resolute Onyx 2.0 drug-eluting stent, Omega-3 fatty acids, safety of drugs used in the treatment of gout (febuxostat versus allopurinol), and preventive strategies for those at risk for renal complications were tested in patients with coronary artery disease. Smokers were compared with nonsmokers presenting with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in terms of clinical, angiographic, and outcomes. Association of influenza infection with acute myocardial infarction was also tested. A good number of trials tested different antiplatelets in different manners. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
